Investment Highlights

With new and unique technologies and active substances, the biopharmaceutical company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.

What sets us apart:

  • Biopharmaceutical company developing ground-breaking immunotherapies
  • Lead product lefitolimod (MGN1703): potential blockbuster candidate
  • Targeting indications with high unmet medical needs: Cancer and HIV
  • Attractive for partnering/licensing: Advanced, close-to-market product candidate with long-term exclusivity and promising next generation successor molecules

The biopharmaceutical company MOLOGEN AG announced today the new dates for the publication of the Annual Financial Statements 2017 on 25 April 2018 and the holding of the Annual General Meeting on 8 June 2018. [more]

Annual Report 2016
Download PDF

Quarterly Statement as at 31 March 2017
Download PDF

Half-year Report as at 30 June 2017
Download PDF

Quarterly Statement as at 30 September 2017

Download PDF

June 8, 2018

Annual General Meeting

April 25, 2018

Annual Report 2017

 

Show complete Corporate Calendar.

24 April 2018

Family Office Capital Day, Vienna, Austria

 

19 April 2018

German Biotechnology Days, Berlin, Germany

 

14 - 18 April 2018

AACR - American Association for Cancer Research, Washington, US

 

19 - 21 March 2018

ITOC - 5 Immunotherapy of Cancer Conference, Berlin, Germany


Show complete calendar.

 

 

 

 

Share Price

Contact:

Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Phone: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.